US Patent 8,722,650: Minocycline Extended-Release Acne Treatment Patent Scope and Landscape

US Patent 8,722,650 protects a narrow, formulation-specific method of treating acne with once-daily oral minocycline. Its central limitations are the 55 mg, 80 mg, or 105 mg dose strengths; lactose monohydrate; hydroxypropylmethylcellulose with a defined hydroxypropoxylation range; and staged dissolution requirements. The patent also covers weight-based dose selection using a prescribing chart or reference tool targeting approximately 1 mg/kg/day.

The patent does not broadly cover all oral minocycline products, all extended-release minocycline formulations, or all acne-treatment methods. Infringement requires practice of the claimed dosing method with a product meeting the specified formulation and dissolution characteristics.

What does US Patent 8,722,650 cover?

The patent has two independent method claims:

Claim	Protected subject matter	Principal limitations
1	Once-daily acne treatment	Human patient; oral dosage form; 55, 80, or 105 mg minocycline; lactose monohydrate; HPMC; specified hydroxypropoxylation; specified dissolution profile
7	Physician-assisted dose selection	Patient weight determination; chart or reference tool; weight ranges tied to dose forms targeting 1 mg/kg/day; administration of the same formulation described in claim 1

Claims 2 through 6 depend from claim 1. Claims 8 through 10 depend from claim 7.

The patent is therefore best characterized as a combination of:

A therapeutic use claim.
A dose-selection claim.
A controlled-release formulation limitation.
A dissolution-performance limitation.
A specific excipient and polymer-substitution limitation.

The formulation and dissolution requirements materially narrow the claims.

How should claim 1 be construed?

Once-daily acne treatment

Claim 1 requires administering the dosage form “once per day” to a human for acne. A product label directing twice-daily administration would not satisfy the express dosing limitation, although actual once-daily use could create a separate infringement issue depending on the evidence and inducement theory.

The claim is a method claim rather than a composition claim. Ownership or manufacture of the tablets alone does not necessarily establish direct infringement of claim 1. Direct infringement generally requires performance of the claimed method, including administration to a human for acne treatment. Induced or contributory infringement theories could still be relevant if a manufacturer promotes a qualifying product for the claimed use. See 35 U.S.C. §§ 271(b)-(c).

Minocycline dose strengths

The claimed minocycline amount must be one of:

55 mg;
80 mg; or
105 mg.

The “selected from the group consisting of” language is closed-ended for the claimed dose limitation. A 45 mg, 65 mg, 90 mg, 100 mg, 115 mg, or 135 mg product would not literally meet this limitation.

The claims also require a dosage form containing minocycline, lactose monohydrate, and HPMC. The claim does not specify minocycline hydrochloride in the text supplied, although the commercial extended-release acne products associated with this technology generally use minocycline hydrochloride.

Hydroxypropylmethylcellulose limitation

Claim 1 requires HPMC that is “at least 8.3 to about 9.8% hydroxypropoxylated.” Dependent claims narrow this range:

Claim	HPMC hydroxypropoxylation
1	At least 8.3% to about 9.8%
4	8.3% to about 9.1%
5	8.9% to 9.1%
7	At least 8.3% to about 9.8%
8	8.3% to about 9.1%
9	8.9% to 9.1%

This limitation is technically important because HPMC substitution affects hydration, gel formation, diffusion, tablet erosion, and drug release. A generic manufacturer could attempt to design around the patent by using:

A different HPMC grade;
A polymer outside the claimed hydroxypropoxylation range;
Another cellulose derivative;
A non-cellulosic release-control polymer; or
A formulation that does not meet the dissolution profile.

A design-around based only on a different supplier is weak if the polymer has the same relevant chemical substitution range.

Dissolution profile

Claim 1 requires all three dissolution stages:

Time point	Required minocycline dissolution
1 hour	About 35% to about 50%
2 hours	About 60% to about 75%
4 hours	At least about 90%

This is a functional product limitation embedded in a method claim. The relevant product must meet the dissolution profile under the applicable test conditions, including the dissolution apparatus, medium, agitation, sampling, and assay method used to establish the claimed ranges.

The profile imposes both lower and upper boundaries at one and two hours. A formulation releasing 55% at one hour could fall outside the literal range, while a formulation releasing only 85% at four hours would fail the final limitation.

The dissolution limitation is likely to be a major litigation issue because minor changes in tablet hardness, particle size, polymer viscosity, granulation, coating, or test conditions can alter release results.

What do claims 2 through 6 add?

Claims 2 and 3: weight-based dosing

Claim 2 requires dosing at approximately 1.1 mg/kg to 0.9 mg/kg of body weight. Claim 3 narrows this to 1 mg/kg.

The range is unusual in presentation because it is written from 1.1 mg/kg down to 0.9 mg/kg. Its practical scope is approximately 0.9 to 1.1 mg/kg/day.

Claim 3 is narrower and commercially significant. It ties the fixed strengths to a weight-based dosing strategy rather than merely prescribing a fixed tablet strength.

For example:

Patient weight	Approximate 1 mg/kg dose	Potential claimed strength
55 kg	55 mg	55 mg
80 kg	80 mg	80 mg
105 kg	105 mg	105 mg

The claim does not expressly require exact weight-to-dose matching in all cases, but the product must provide the claimed dose per kilogram under the selected administration regimen.

Claims 4 and 5: narrower HPMC ranges

Claims 4 and 5 create fallback positions if the broad HPMC range in claim 1 is invalidated or narrowly construed. Claim 5 is particularly narrow, requiring HPMC hydroxypropoxylation of 8.9% to 9.1%.

A narrower polymer range may be easier to prove analytically but may also be more vulnerable to a manufacturing change that shifts the polymer outside the range.

Claim 6: lactose in two processing locations

Claim 6 requires lactose monohydrate in both:

An intragranular component; and
An extragranular component.

This is a process-structure limitation. It distinguishes a formulation in which lactose is divided between the granulation phase and the external blending phase from a formulation using lactose only intragranularly or only extragranularly.

The limitation may require review of batch records, master manufacturing documents, formulation-development records, and tablet composition. Finished-product testing alone may not establish whether lactose was used in both processing locations.

What does claim 7 protect?

Claim 7 covers a prescribing-support method involving four steps:

Determining the patient’s body weight.
Referring to a chart or reference tool correlating weight ranges with different minocycline dosage forms.
Selecting one dosage form corresponding to the patient’s weight range.
Administering that dosage form.

The chart must be based on a target dose rate of 1 mg/kg/day. The selected dosage form must contain the same three strengths, excipients, polymer characteristics, and dissolution profile required by claim 1.

Claim 7 is not a standalone software claim. A chart, calculator, electronic medical-record rule, or dosing algorithm could potentially perform the reference-tool function, but the claim also requires administration of the qualifying oral dosage form.

How strong is the patent estate based on the asserted claims?

The patent has moderate technical specificity and potentially meaningful commercial coverage if the covered strengths and formulation correspond to an approved branded product.

Strengths

The dissolution profile creates a measurable product fingerprint.
The claim combines dose, excipient, polymer, and performance limitations.
The 55 mg, 80 mg, and 105 mg strengths align with weight-based dosing.
Dependent claims provide narrower positions for HPMC substitution and lactose placement.
Claim 7 can reach prescribing systems that direct physicians toward the claimed dose-selection method.

Vulnerabilities

The claims are methods, not broad composition claims.
Every limitation must be met for literal infringement.
Dissolution results may vary with test conditions.
HPMC hydroxypropoxylation may be difficult to establish from public product information.
Lactose processing location may require discovery of manufacturing records.
The 1 mg/kg concept may face prior-art scrutiny if weight-based minocycline dosing was previously disclosed.
Fixed-strength alternatives outside 55 mg, 80 mg, and 105 mg may avoid the claims.

The claim set is stronger against a generic that copies the branded product’s strengths and release system than against a competitor using different strengths or a materially different release-control technology.

What patents protect the associated minocycline acne product?

US Patent 8,722,650 should be analyzed as one member of a broader minocycline extended-release patent family and product patent estate. The relevant protection categories are:

Protection category	Relevance to US 8,722,650
Active ingredient	Limited; the claims do not broadly cover minocycline
Extended-release formulation	Central
Polymer composition	Central
Dissolution profile	Central
Dose strength	Central
Weight-based dosing	Central in claims 2, 3, and 7
Acne method of use	Central
Manufacturing process	Indirectly relevant through claim 6
Pediatric exclusivity	Regulatory, not established by the claim text
New chemical entity exclusivity	Not applicable to an old active ingredient
Biosimilar exclusivity	Not applicable; minocycline is a small molecule

Other patents in the product estate may cover different release formulations, dose regimens, or manufacturing features. They must be separated from US 8,722,650 because a patent family can contain continuation applications with materially different claim scope.

When does US Patent 8,722,650 lose exclusivity?

The patent issued on May 13, 2014. Patent expiration is not determined by the issue date. For a utility patent, the ordinary term is generally 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and applicable priority rules. See 35 U.S.C. §§ 154 and 156.

The precise expiration date cannot be established from the claims supplied. The controlling analysis requires the patent’s front-page priority chain and USPTO term calculation. A later-issued continuation can expire on the same date as an earlier application in the chain when it claims priority to that earlier nonprovisional filing.

FDA regulatory exclusivity must be analyzed separately from patent term. Minocycline is an established active ingredient, so new chemical entity exclusivity is not the principal regulatory barrier. Any pediatric exclusivity, orphan exclusivity, or other FDA exclusivity would depend on the approved NDA history rather than the patent claims. FDA’s Orange Book is the relevant source for listed patents and regulatory exclusivity. [2]

What is the Orange Book status of US 8,722,650?

A patent’s inclusion in the Orange Book is not established by the patent document itself. Orange Book listing is an NDA-holder submission accepted by FDA under the applicable regulatory framework.

For a listed drug, the key questions are whether US 8,722,650 is:

Listed against the relevant NDA;
Identified as covering the drug substance, drug product, or method of use;
Subject to a use code;
Still listed or administratively delisted; and
Relevant to an ANDA applicant’s Paragraph IV certification.

A method-of-use patent may be listed with a use code that is narrower than the full claim language. A listing does not itself prove validity or infringement, and an Orange Book omission does not eliminate potential patent claims under the Patent Act.

What Paragraph IV challenges could target the patent?

An ANDA applicant could challenge the patent through a Paragraph IV certification alleging that the patent is invalid, unenforceable, or will not be infringed by the proposed product. See 21 U.S.C. § 355(j)(2)(A)(vii)(IV).

Potential challenge theories include:

Anticipation

The challenger would need a single prior-art reference disclosing all limitations, including:

One of the three specified strengths;
Lactose monohydrate;
HPMC within the claimed hydroxypropoxylation range;
The three-stage dissolution profile;
Once-daily acne treatment; and
For claim 7, the weight-based chart and administration steps.

The combination of formulation and dissolution limitations makes complete anticipation more difficult than anticipation of a basic minocycline acne method.

Obviousness

The likely obviousness case would combine prior art on:

Extended-release minocycline;
Once-daily acne treatment;
Weight-based dosing near 1 mg/kg/day;
HPMC-controlled release;
Lactose-containing tablets; and
Target dissolution profiles.

The patentee would likely rely on the selected polymer range, release behavior, dose strengths, and clinical tolerability as evidence of non-obvious formulation optimization. The strength of that defense depends on the priority-date record and experimental data.

Indefiniteness

Potential issues include:

The meaning of “about” in the dissolution ranges;
The phrase “at least 8.3 to about 9.8%”;
The scope of “a chart or reference tool”;
The relationship between the 0.9 to 1.1 mg/kg range and the discrete strengths.

The patent specification and prosecution history would control how these terms are interpreted.

Non-infringement

A generic applicant could avoid infringement by using:

Different strengths;
A different active-release mechanism;
HPMC outside the claimed substitution range;
A dissolution profile outside one or more ranges;
A different dosing frequency;
A product without lactose monohydrate; or
A formulation in which lactose is not present in both granulation components.

What generic launch risks exist?

The highest-risk generic scenario is a product that copies the branded formulation and label:

55 mg, 80 mg, or 105 mg strength;
Once-daily acne indication;
Weight-based dosing near 1 mg/kg/day;
HPMC extended-release system;
Lactose-containing formulation;
Comparable dissolution profile.

A lower-risk design would use a different strength matrix, polymer system, release profile, or approved indication. The risk analysis must distinguish product similarity for FDA approval from patent infringement. FDA may approve a product that is not identical to the reference formulation, while the patent holder may still assert infringement if the marketed product practices every claim limitation.

What litigation and settlement issues matter?

A complete litigation assessment requires review of PACER, USPTO Patent Center, FDA Orange Book certifications, and ANDA litigation records. The material legal events to track are:

Event	Business significance
Paragraph IV notice	Starts potential Hatch-Waxman litigation
45-day filing period	Determines whether a 30-month stay may arise
ANDA suit	Frames validity and infringement issues
Preliminary injunction request	Can affect launch timing
Settlement agreement	May establish an authorized generic or delayed-entry date
Consent judgment	May resolve infringement without full trial
Patent-term adjustment	Changes the practical entry date
Orange Book delisting	Can alter ANDA certification obligations

No biosimilar challenge is relevant. Minocycline is a small-molecule drug regulated through the ANDA pathway, not the biosimilar pathway under section 351(k) of the Public Health Service Act. [3]

How does US 8,722,650 compare with broad minocycline patents?

US 8,722,650 is narrower than a patent claiming minocycline generally or an extended-release minocycline composition without performance parameters.

Patent type	Relative breadth	Main commercial effect
Minocycline compound patent	Broad, if valid and unexpired	Can block all covered uses and formulations
Broad extended-release composition patent	Medium to broad	Can affect multiple strengths and indications
US 8,722,650	Narrow to medium	Targets specific strengths, excipients, polymer range, dissolution, and acne dosing
Weight-based method patent	Narrow method coverage	Depends heavily on labeling and actual prescribing
Manufacturing patent	Variable	Can block a process without blocking all products

The patent’s commercial value depends less on the minocycline molecule and more on whether its formulation limitations map onto the reference product and likely ANDA products.

Key Takeaways

US Patent 8,722,650 is a formulation-specific acne treatment patent, not a broad minocycline patent.
Independent claim 1 requires once-daily administration of a 55 mg, 80 mg, or 105 mg dosage form.
The claimed product must contain lactose monohydrate and HPMC within a defined hydroxypropoxylation range.
The dissolution profile is a critical limitation: approximately 35% to 50% at one hour, 60% to 75% at two hours, and at least 90% at four hours.
Claims 2 and 3 add approximately 0.9 to 1.1 mg/kg/day and 1 mg/kg/day dosing.
Claim 6 requires lactose monohydrate in both intragranular and extragranular components.
Claim 7 covers a weight-based prescribing chart or reference tool linked to the same formulation.
The most credible generic design-arounds use different strengths, polymers, dissolution behavior, excipients, or dosing schedules.
Minocycline is a small molecule, so biosimilar analysis does not apply.
Orange Book listing, patent-term adjustment, Paragraph IV activity, litigation, and settlement status must be determined from the current FDA and USPTO records, not from the claim text alone.

FAQs

Is US Patent 8,722,650 a composition patent?

No. The supplied claims are method claims. They require treatment or prescribing conduct involving a dosage form with specified formulation and dissolution characteristics.

Does a 135 mg minocycline tablet infringe claim 1?

Not literally under the specified dose limitation. Claim 1 lists only 55 mg, 80 mg, and 105 mg. A separate analysis under the doctrine of equivalents could be considered, but it would depend on the prosecution history and the technical differences between the products.

Can a generic use a different HPMC supplier?

Yes, potentially. Supplier identity alone is not decisive. The relevant question is whether the HPMC has the claimed hydroxypropoxylation range and whether the final product satisfies the dissolution limitations.

Does FDA approval establish infringement of US 8,722,650?

No. FDA approval and patent infringement are separate inquiries. Approval evaluates safety, effectiveness, quality, bioequivalence, and regulatory requirements. Infringement depends on whether the marketed product and conduct meet the patent claims.

Are prescribing charts independently protected by claim 7?

Claim 7 requires more than a chart. It requires determining body weight, consulting the chart or reference tool, selecting the corresponding dosage form, and administering the claimed minocycline formulation.

References

U.S. Patent No. 8,722,650, “Methods of treating acne,” issued May 13, 2014. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
U.S. Food and Drug Administration. (n.d.). Biosimilar and interchangeable products. https://www.fda.gov/drugs/biosimilars
United States Code. 35 U.S.C. §§ 154, 156, 271.
United States Code. 21 U.S.C. § 355(j).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006262428	⤷ Start Trial
Canada	2613273	⤷ Start Trial
China	101208097	⤷ Start Trial
European Patent Office	1898925	⤷ Start Trial
Japan	2008543936	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,722,650

Summary for Patent: 8,722,650